Item 8.01. Other Events.
On February 1, 2021, DuPont de Nemours, Inc. ("DuPont" or the "Company")
completed the separation and distribution of the Nutrition & Biosciences
business segment (the "N&B Business"), and merger of Nutrition & Biosciences,
Inc. ("N&B"), a DuPont subsidiary formed to hold the N&B Business, with a
subsidiary of International Flavors & Fragrances Inc. ("IFF"). In conjunction
with the closing of the N&B Transaction, the Company also changed its management
and reporting structure.

DuPont is filing this Current Report on Form 8-K to recast its consolidated
financial statements in the Company's Annual Report on Form 10-K for the year
ended December 31, 2020 filed with the Securities and Exchange Commission
("SEC") on February 12, 2021 (the "2020 Form 10-K") to reflect the presentation
of the N&B Business as discontinued operations and to reflect the changes in the
Company's reportable segments.

The Company has revised the following portions of its 2020 Form 10-K to reflect the presentation of its N&B business as discontinued operations and, where applicable, changes to its reportable segments:



•Part 1, Item 1. Business
•Part 1, Item 2. Properties
•Part II, Item 7. Management's Discussion and Analysis of Financial Condition
and Results of Operations
•Part II, Item 7A. Quantitative and Qualitative Disclosures about Market Risk
•Part II, Item 8. Financial Statements and Supplementary Data
•Part IV, Item 15. Exhibits, Financial Statement Schedules

Except as specifically set forth herein as required to reflect the historical
results of the N&B business as discontinued operations and to reflect the change
in the Company's reporting structure, this filing does not purport to update for
any other information, developments, transactions, risks or any other known
trends, events or uncertainties that have arisen since the Company's 2020 Form
10-K was filed on February 12, 2021 or are otherwise known to management. More
current information regarding events subsequent to the Company filing its 2020
Form 10-K on February 12, 2021 is contained in the Company's first quarterly
report on Form 10-Q for the period ended March 31, 2021, filed with the SEC on
May 4, 2021, ("2021 Q1 Form 10-Q") and other SEC filings made subsequent to the
filing of the 2020 Form 10-K. This Form 8-K should be read in conjunction with
the Company's 2020 Annual Report on Form 10-K and those other subsequent filings
with the SEC, including its 2021 Q1 Form 10-Q. These subsequent SEC filings
contain important information regarding events, risks, developments and updates
affecting the Company and its expectations that have occurred since the filing
of the Company's 2020 Form 10-K. The information contained herein is not an
amendment to, or a restatement of, the Company's 2020 Form 10-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

23.1 Consent of Independent Registered Public Accounting Firm, PricewaterhouseCoopers LLP.

23.2 Consent of Independent Registered Public Accounting Firm, Deloitte & Touche LLP.

23.3 Consent of Independent Registered Public Accounting Firm, Deloitte & Touche LLP.

23.4 Consent of Independent Registered Public Accounting Firm, PricewaterhouseCoopers LLP.


                As Recasted Part I, Item 1. Business and Item 2.

Properties. As Recasted Part II, Item

99.1 7. Management's Discussion and Analysis of Financial Condition and Results of


                Operations, Item 7A. Quantitative and Qualitative

Disclosures About Market Risk and


                Item 8. Financial Statements and Supplementary Data. As

Recasted Part IV, Item 15.


                Exhibits, Financial Statement Schedules.

104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses